Delivery Order SPE2DR25D2102-SPE2DR26FB2PZ
- Not listed
- The Defense Logistics Agency awarded a $3,231.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Mycophenolate 200 mg/mL suspension in 160 mL quantities, with an ultimate completion date of November 12, 2025. This non-set-aside, competitively awarded contract is being performed at the company's Conshohocken, Pennsylvania location and represents a single delivery order under AmerisourceBergen's larger contract vehicle with DLA. This...
- The Defense Logistics Agency awarded a $3,984.81 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mycophenolate 200 mg/mL suspension (160 mL) on January 9, 2026, with an ultimate completion date of January 12, 2026. This non-set-aside contract represents a small-value transaction issued under the company's existing pharmaceutical supply framework. The drug will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $1,288.62 to AmerisourceBergen Drug Corp for Mycophenolate 200 mg/mL suspension (160 mL) on December 26, 2025, with completion targeted for December 29, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $3,022.37 to AmerisourceBergen Drug Corp for the supply of Mycophenolate 200 mg/mL suspension (160 mL) on September 18, 2025, with completion targeted for September 19, 2025. This is a firm fixed price, non-set-aside contract performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $1,014.21 to AmerisourceBergen Drug Corp for the supply of Mycophenolate 200 mg/mL Suspension in a 160 mL unit. The contract was awarded on January 7, 2026, with an ultimate completion date of January 8, 2026, and utilizes firm fixed-price pricing. The award was not designated as a set-aside contract, indicating competitive selection among qualified vendors. Performance of this delivery order will take place at the awardee's...
- The Defense Logistics Agency awarded a delivery order valued at $1,120.33 to AmerisourceBergen Drug Corp for 500 mg mycophenolate tablets (500 count) on January 13, 2026, with an ultimate completion date of January 14, 2026. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp operates as a subsidiary of Cencora, Inc., a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Mycophenolate 200 mg/mL suspension in 160 mL quantities, with a contract ceiling value of $1,326.21. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion on September 16, 2025, and will be performed at the vendor's Conshohocken, Pennsylvania location. The award carries no set-aside designation, indicating the contract was...
- The Defense Logistics Agency has awarded a delivery order valued at $2,990.28 to AmerisourceBergen Drug Corp for 100 tablets of Mycophenolate 500 mg, with an ultimate completion date of April 23, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively on April 22, 2025. The pharmaceutical product will be delivered to Conshohocken, PA, where AmerisourceBergen Drug Corp maintains its corporate office and primary operations. This delivery order is issued...
- The Defense Logistics Agency awarded a $1,346.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Mycophenolate 500 mg vials. This contract, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a non-competitive set-aside delivery order executed through the company's existing indefinite delivery contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a competitively-competed delivery order to AmerisourceBergen Drug Corp for the supply of Mycophenolate 500 mg tablets (100-count packages) with a contract value of $15,907.80. The award was issued on January 23, 2026, with an ultimate completion date of January 26, 2026, and is structured as a firm fixed-price delivery order. The place of performance is located in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters. This...
- SPE2DR25D2102Indefinite Delivery Contract
- SPE2DR25D2102-SPE2DR26FB2PZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,351.56 to AmerisourceBergen Drug Corp for the supply of Mycophenolate 200 mg/ml suspension in 160 ml quantities. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by February 3, 2026. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s comprehensive Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031. The IDC serves as a global pharmaceutical supply vehicle enabling the company to deliver a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide, including service to the Defense Health Agency, U.S. Coast Guard, and other federal medical institutions. Mycophenolate, an immunosuppressant medication commonly used in transplant care and autoimmune disease management, represents a specialized pharmaceutical product within the company's extensive federal medical supply portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 2/1/26 |